ArticleBMC infectious diseases2025
Extended-spectrum-β-lactamase-producing Gram-negative bacteria are associated with high mortality in children with bloodstream infections in Dar es Salaam, Tanzania.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesStudies from Tanzania show rising prevalence of extended-spectrum β-lactamase (ESBL) amongst key bacterial pathogens. We aimed to look at the clinical impact of bloodstream infections (BSI) caused by ESBL producing Gram-negative bacteria (GNB). This study was carried out on hospitalised children aged less than five years from four hospitals of the region of Dar es Salaam.
methodsThe study included 135 hospitalized children with BSI due to GNB which were screened for ESBL. Clinical outcome i.e., death or discharge, was known for 130 children of which 12% (n = 15) died We used univariate and multivariate regression analyses to compare the outcome i.e., in-hospital mortality and length of hospital stay of inpatients with BSI caused by ESBL- producing GNB vs. outcome of inpatients with BSI caused by non ESBL producing GNB.
resultsOf the 135 children, 69 (51%) and 66 (49%) had BSI due to ESBL and non-ESBL producers respectively. Of the 15 children who died, 73% had BSI due to Klebsiella pneumoniae or Escherichia coli. Mortality among children with infections caused by ESBL and non-ESBL producers were 16% and 6%, respectively. After adjusting for differences between groups regarding age, sex, and consciousness status on admission, infection with ESBL producing bacteria was a significant predictor of mortality, OR = 29; 95% CI (1.5-540). Children infected with ESBL producing GNB had longer duration of hospital stay, OR 3.2, 95% CI (1.3-7.8). Resistance towards antimicrobial agents other than penicillin's and cephalosporins was significantly higher among ESBL producers than non-ESBL producers e.g. gentamicin (60/69, 87%) vs. (6/66, 9.1%), OR = 67; 95% CI (22.3-198.9) and ciprofloxacin (37/69, 54%) vs. (7/66, 10.6%), OR = 8; 95%CI (3.9-24.3).
conclusionsThe rapidly increasing resistance to commonly used and affordable antibiotics increases the risk of death and prolongs hospital stays in neonates in the study setting. These findings highlight the need for strengthened infection prevention and control in community settings and appropriate antibiotic use to reduce the selection and spread of ESBL-GNB in hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.